ImmunoGen

ImmunoGen develops targeted anticancer therapeutics, including a proprietary Targeted Antibody Payload (TAP) technology. Read more

Mark Enyedy's photo - President & CEO of ImmunoGen

President & CEO

Mark Enyedy

CEO Approval Rating

81/100

Founded:

1980

Status:

PublicIndependent CompanyNASDAQIMGN

IMMUNOGEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Endocyte is one of ImmunoGen's top rivals. Endocyte was founded in West Lafayette, Indiana} in 1995. Like ImmunoGen, Endocyte also competes in the Pharmaceuticals space. Compared to ImmunoGen, Endocyte generates $134.6M less revenue.

Amgen is ImmunoGen's #2 competitor. Amgen was founded in 1980, and is headquartered in Thousand Oaks, California. Like ImmunoGen, Amgen also operates in the Pharmaceuticals space. Amgen generates $25B more revenue vs. ImmunoGen.

MacroGenics is a top competitor of ImmunoGen. MacroGenics's headquarters is in Rockville, Maryland, and was founded in 2000. Like ImmunoGen, MacroGenics also works within the Biotechnology sector. MacroGenics generates 80% of ImmunoGen's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Puma Biotechnology a competitor of ImmunoGen?

ImmunoGen Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$134.7M

ImmunoGen's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 7.1B. Over the last four quarters, ImmunoGen's revenue has grown by 4.5%. Specifically, in Q1 2021's revenue was $15.7M; in Q4 2020, it was $85.8M; in Q3 2020, it was $18.2M; in Q2 2020, ImmunoGen's revenue was $15M.

ImmunoGen Acquisitions

No recent acquisitions found related to ImmunoGen

ImmunoGen Funding History

Since ImmunoGen was founded in 1980, it has participated in 2 rounds of funding. In total ImmunoGen has raised $3.0M. ImmunoGen's last funding round was on Nov 2011 for a total of $1.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Angel
Nov 2011
$1M
Unattributed
Jun 2011
$2M
-

Since ImmunoGen was founded in 1980, it has participated in 2 rounds of funding. In total ImmunoGen has raised $3.0M. ImmunoGen's last funding round was on Nov 2011 for a total of $1.0M

ImmunoGen Investments

No recent investments found related to ImmunoGen

ImmunoGen News

April 10, 2021MarketScreener

Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting

(marketscreener.com) First-in-Class ADAM9-Targeting ADC Demonstrates Anti-Tumor Activity in Multiple ... See more »
April 1, 2021BioSpace

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of canc... See more »
March 1, 2021MarketScreener

Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(marketscreener.com) ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates for... See more »
February 24, 2021Seeking Alpha

Major Catalysts This Year

February 24, 2021MarketScreener

Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

(marketscreener.com) ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates for... See more »
February 16, 2021Pulse2.0

Why It Happened

The stock price of ImmunoGen, Inc. (NASDAQ: IMGN) increased by 30.32% on Friday, February 12. This is... See more »

ImmunoGen Press Releases

January 16, 2019CENTRALCHARTS

VBI Vaccines Appoints Blaine McKee to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing nex... See more »
May 14, 2018Business Wire

Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V. announced today the expansion of its Scientific Advisory Bo... See more »
April 26, 2018BioCentury

MANAGEMENT TRACKS

Cancer company ImmunoGen Inc. (NASDAQ:IMGN) hired Blaine McKee as chief business officer and EVP. He ... See more »
February 7, 2018Business Wire

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of a... See more »
October 12, 2017Business Wire

ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN) today announced the closing of its pr... See more »
March 16, 2017Accesswire

TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention

NEW YORK, NY / ACCESSWIRE / March 16, 2017 / One question many investors have is how much emphasis sh... See more »
November 18, 2016Blackbird

John Lambert, ImmunoGen to Present at GTCbio's Antibody Drug Conjugates Conference

BOSTON, MA, November 18, 2016 /24-7PressRelease/ - John Lambert, Executive Vice President at ImmunoGe... See more »

ImmunoGen Videos

May 14, 2018ImmunoGen Youtube Channel

"ImmunoGen: Brand Launch" on YOUTUBE

May 9, 2018ImmunoGen Youtube Channel

"ImmunoGen Anthem" on YOUTUBE

May 7, 2018ImmunoGen Youtube Channel

"ImmunoGen Careers" on YOUTUBE

May 1, 2018ImmunoGen Youtube Channel

"ImmunoGen Culture" on YOUTUBE

Social Media

ImmunoGen Headquarters

830 Winter Street

Waltham, Massachusetts02451

781-895-0600

Driving Directions »

Trending Companies

ImmunoGen Summary

ABOUT

Overview

ImmunoGen develops targeted anticancer therapeutics, including a proprietary Targeted Antibody Payload (TAP) technology. ImmunoGen was founded in 1980. ImmunoGen's headquarters is located in Waltham, Massachusetts, USA 02451. It has raised 3.0M in 2 r...

CEO

ImmunoGen's President & CEO, Mark Enyedy, currently has an approval rating of 81%. ImmunoGen's primary competitors are Endocyte, Amgen & MacroGenics.

Frequently Asked Questions about ImmunoGen

  1. When was ImmunoGen founded?

    ImmunoGen was founded in 1980
  2. Who is ImmunoGen's CEO?

    ImmunoGen's CEO is Mark Enyedy
  3. How much revenue does ImmunoGen generate?

    ImmunoGen generates $134.7M in revenue
  4. How much funding does ImmunoGen have?

    ImmunoGen has historically raised $3M in funding
  1. Where is ImmunoGen's headquarters?

    ImmunoGen's headquarters is in Waltham Massachusetts, USA
  2. How many employees does ImmunoGen have?

    ImmunoGen has 296 employees
  3. What sector does ImmunoGen operate in?

    ImmunoGen is in Pharmaceuticals, Biotechnology
  4. Who are ImmunoGen's competitors?

    ImmunoGen's top competitors are Endocyte, Amgen, MacroGenics